Premium
Lobomycosis: an emerging disease in humans and delphinidae
Author(s) -
PanizMondolfi A.,
Talhari C.,
Sander Hoffmann L.,
Connor D. L.,
Talhari S.,
BermudezVillapol L.,
HernandezPerez M.,
Van Bressem M. F.
Publication year - 2012
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/j.1439-0507.2012.02184.x
Subject(s) - disease , biology , etiology , antifungal , fungus , tropical disease , dermatology , medicine , ecology , pathology , botany
Summary Lobomycosis, a disease caused by the uncultivable dimorphic onygenale fungi Lacazia loboi , remains to date as an enigmatic illness, both due to the impossibility of its aetiological agent to be cultured and grown in vitro , as well as because of its unresponsiveness to specific antifungal treatments. It was first described in the 1930s by Brazilian dermatologist Jorge Lobo and is known to cause cutaneous and subcutaneous localised and widespread infections in humans and dolphins. Soil and vegetation are believed to be the chief habitat of the fungus, however, increasing reports in marine mammals has shifted the attention to the aquatic environment. Infection in humans has also been associated with proximity to water, raising the hypothesis that L. loboi may be a hydrophilic microorganism that penetrates the skin by trauma. Although its occurrence was once thought to be restricted to New World tropical countries, its recent description in African patients has wrecked this belief. Antifungals noted to be effective in the empirical management of other cutaneous/subcutaneous mycoses have proven unsuccessful and unfortunately, no satisfactory therapeutic approach for this cutaneous infection currently exists.